scispace - formally typeset
T

Tracy E Roberts

Researcher at University of Birmingham

Publications -  196
Citations -  8326

Tracy E Roberts is an academic researcher from University of Birmingham. The author has contributed to research in topics: Randomized controlled trial & Cost effectiveness. The author has an hindex of 42, co-authored 182 publications receiving 7002 citations. Previous affiliations of Tracy E Roberts include City Hospitals Sunderland NHS Foundation Trust & National Institute for Health Research.

Papers
More filters
Journal ArticleDOI

The correct approach to modelling and evaluating chlamydia screening.

TL;DR: A recent systematic review of economic evaluations suggests that screening for genital chlamydia infection is “cost effective,” but how this conclusion was reached is concerned since the reviewers did not take into account the fact that Chlamydia trachomatis is infectious.
Journal ArticleDOI

Uterotonic Drugs for the Prevention of Postpartum Haemorrhage: A Cost‐Effectiveness Analysis

TL;DR: The results suggest carbetocin, oxytocin and ‘ergometrine plus Oxytocin’ could all be favourable options for being the most cost-effective strategy for preventing postpartum haemorrhage.
Journal ArticleDOI

Cost-effectiveness of sentinel lymph node biopsy vs inguinofemoral lymphadenectomy in women with vulval cancer.

TL;DR: SLN biopsy using 99mTc and blue dye with ultrastaging may be considered the most cost-effective strategy based on the outcome of survival free of morbidity for 2 years, but findings here indicate that using blue dye and H&E for the identification of the SLN and the Identification of metastasis, respectively, are not sensitive enough to be used on their own.
Journal ArticleDOI

Economic evaluation of Faecal microbiota transplantation compared to antibiotics for the treatment of recurrent Clostridioides difficile infection.

TL;DR: Evaluating the cost effectiveness of FMT for rCDI using the latest and best evidence showed that FMT is a less costly and more effective treatment than either fidaxomicin or vancomycin.